Outcomes in COVID-19 metronidazole studies

All studies   ICU   Hospitalization   Serious outcomes   RCTs   Peer-reviewed   All outcomes  
0 0.5 1 1.5+ All studies -20% 1 44 Improvement, Studies, Patients Relative Risk ICU admission -20% 1 44 Hospitalization 25% 1 44 RCTs -20% 1 44 Late -20% 1 44 Metronidazole for COVID-19 c19early.org November 2025 Favorsmetronidazole Favorscontrol
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Kazempour (SB RCT) -20% 1.20 [0.19-7.77] ICU 2/20 2/24 Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.86 Late treatment -20% 1.20 [0.19-7.77] 2/20 2/24 20% higher risk All studies -20% 1.20 [0.19-7.77] 2/20 2/24 20% higher risk 1 metronidazole COVID-19 study c19early.org November 2025 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.86 Effect extraction pre-specified(most serious outcome) Favors metronidazole Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Kazempour (SB RCT) -20% 1.20 [0.19-7.77] 2/20 2/24 Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.86 Late treatment -20% 1.20 [0.19-7.77] 2/20 2/24 20% higher risk All studies -20% 1.20 [0.19-7.77] 2/20 2/24 20% higher risk 1 metronidazole COVID-19 ICU result c19early.org November 2025 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.86 Favors metronidazole Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Kazempour (SB RCT) 25% 0.75 [0.01-47.2] hosp. time 20 (n) 24 (n) Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.9 Late treatment 25% 0.75 [0.01-47.2] 20 (n) 24 (n) 25% lower risk All studies 25% 0.75 [0.01-47.2] 20 (n) 24 (n) 25% lower risk 1 metronidazole COVID-19 hospitalization result c19early.org November 2025 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.9 Favors metronidazole Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Kazempour (SB RCT) -20% 1.20 [0.19-7.77] ICU 2/20 2/24 Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.86 Late treatment -20% 1.20 [0.19-7.77] 2/20 2/24 20% higher risk All studies -20% 1.20 [0.19-7.77] 2/20 2/24 20% higher risk 1 metronidazole COVID-19 serious outcome c19early.org November 2025 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.86 Effect extraction pre-specified(most serious outcome) Favors metronidazole Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Kazempour (SB RCT) -20% 1.20 [0.19-7.77] ICU 2/20 2/24 Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.86 Late treatment -20% 1.20 [0.19-7.77] 2/20 2/24 20% higher risk All studies -20% 1.20 [0.19-7.77] 2/20 2/24 20% higher risk 1 metronidazole COVID-19 Randomized Controlled Trial c19early.org November 2025 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.86 Effect extraction pre-specified(most serious outcome) Favors metronidazole Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Kazempour (SB RCT) -20% 1.20 [0.19-7.77] ICU 2/20 2/24 Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.86 Late treatment -20% 1.20 [0.19-7.77] 2/20 2/24 20% higher risk All studies -20% 1.20 [0.19-7.77] 2/20 2/24 20% higher risk 1 metronidazole COVID-19 peer reviewed studies c19early.org November 2025 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.86 Effect extraction pre-specified(most serious outcome) Favors metronidazole Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Kazempour (SB RCT) -20% 1.20 [0.19-7.77] ICU 2/20 2/24 Improvement, RR [CI] Treatment Control Kazempour (SB RCT) 25% 0.75 [0.01-47.2] hosp. time 20 (n) 24 (n) Kazempour (SB RCT) -43% 1.43 [0.11-19.3] oxygen 20 (n) 24 (n) Metronidazole COVID-19 outcomes c19early.org November 2025 Favors metronidazole Favors control